GYKI 52895

GYKI 52895

Clinical data
Other names	4-(8,9-Dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)benzenamine
Identifiers
IUPAC name 4-{13-methyl-4,6-dioxa-11,12-diazatricyclo[7.5.0.03,7]tetradeca-1,3(7),8,10-tetraen-10-yl}aniline
JSmol)	Interactive image
SMILES O1c2c(OC1)cc3c(c2)C(=N/NC(C3)C)\c4ccc(N)cc4
InChI InChI=1S/C17H17N3O2/c1-10-6-12-7-15-16(22-9-21-15)8-14(12)17(20-19-10)11-2-4-13(18)5-3-11/h2-5,7-8,10,19H,6,9,18H2,1H3 Y Key:AQTITSBNGSVQNZ-UHFFFAOYSA-N Y
(verify)

GYKI 52895 is a drug which is a 2,3-

Egis Pharmaceuticals began clinical development of the drug in 1997 for major depressive disorder and Parkinson's disease, but it was discontinued in 2001.^[4]

See also

• GYKI 52466, another 2,3-benzodiazepine with other than GABAergic function
• Tifluadom
• Lufuradom
• Benzodiazepine
• Substituted methylenedioxyphenethylamine

References